(MNTA)—Confirmed on today’s MYL CC that FDA recently sent MYL a list of questions about the Copaxone ANDA and that MYL has not yet replied (although they say they plan to reply soon).
Sounds like MYL is at least a year away from potential FDA approval.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.